Business Wire

TX-FLUENCE

1.2.2024 14:31:34 CET | Business Wire | Press release

Share
Fluence and Innexo BV’s Research Partnership Explores Eliminating Vegetation Phase to Drive Potential Energy Savings for Growers

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the successful continuation of its partnership with Dutch organization Innexo BV (Innexo), a specialty agricultural contract research organization that focuses on molecular farming and medicinal plants.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201728532/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fluence and Innexo's partnership tests the effects of eliminating the vegetation phase for cannabis cultivation. (Photo: Business Wire)

Fluence and Innexo’s research partnership is focused on assessing the viability of cultivating cannabis without a standard vegetative phase, a practice generally associated with lower energy use that passes savings directly to growers in Europe and around the globe. Preliminary data from Fluence and Innexo demonstrates the potential of the “no-veg” growing method to help growers save money while improving quality and consistency. The Fluence and Innexo teams intend to collaborate on a full-scale research project to validate these initial results.

“At Innexo, we use our deep knowledge of cannabis cultivars and best propagation practices to help growers create the most efficient cultivation strategies possible,” said Dominique van Gruisen, managing director of Innexo. “We naturally gravitate toward partners like Fluence who can match our expertise and commitment to investing in innovative and impactful cannabis research.”

Most commercial cannabis cultivators use a vegetative phase to ensure proper plant growth to support flower weight and to gain a full and dense canopy. This phase can last anywhere between seven days and four weeks, requiring a significant investment of time, electrical energy and resources. Initial findings from Fluence and Innexo demonstrate the potential of this method to maintain crop quality and yield while creating up to 55% savings on annual electrical costs directly associated with lighting.

When the plants would typically enter the vegetative phase, they were instead transplanted to the flowering room, where they immediately received their maximum light intensity. In this system, cannabis crops reach their final height—between 70 and 120 cm—around 28 days after transplant. Eliminating two weeks of vegetative phase represents up to 252 hours of direct electricity savings per light per crop cycle. Additional savings are realized through lower HVAC costs and generally more efficient cultivation cycles. Initial research indicates that “no-veg” growing is most effective with plant densities between eight and 10 plants per m2. Thus far, research has tested the viability of “no-veg” growing across six cannabis cultivars, 10 different nutrient lines and a wide range of light intensities.

“Proper lighting—which must include a strong combination of advanced fixtures and lighting strategy—plays a critical role in creating a more efficient and profitable methodology for cannabis cultivation,” said Dr. David Hawley, principal scientist at Fluence. “This research demonstrates the value of examining and investing in a research-backed lighting strategy from day one. Our goal is to explore, validate and demonstrate the effectiveness of diverse cultivation strategies to ensure every grower can apply data-driven methodologies to their facilities in collaboration with Fluence.”

Fluence and Innexo’s research uncovered potential savings for growers who pursue growing without a vegetative phase, including an average of both 40% lower electrical costs and up to 40% lower labor costs per crop cycle. Because of the fast-paced growth of the plants, researchers found there was less time for pests and diseases to develop, leading to a healthier end product. In addition, this method could reduce waste by eliminating C-Grade flower, which allows for more crop cycles per year and increases overall predictability for growers.

“At Fluence, we create value for growers throughout the world by investing in research that will expand the horizons of traditional cultivation,” said Sebastian Olschowski, research project manager for EMEA at Fluence. "As plant lighting specialists, we are proud to be part of this project to shape the future of cannabis research and transfer valuable knowledge to our customers and partners.”

Fluence and Innexo’s research collaboration, which began in 2022, has expanded to include collaborations in three of Innexo’s Acceleration Platform for Innovation (API) programs. API empowers innovative, small-scale companies adjacent to the cannabis industry to perform research in medical cannabis cultivation.

For more information on Fluence and its ongoing global research initiatives, visit www.fluence-led.com.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis, produce and flower markets, committed to enabling more efficient crop production for the world’s top greenhouse and indoor growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Professional Business. For more information about Fluence, visit www.fluence-led.com.

About Innexo BV

Innexo BV is a specialty agricultural contract research organization (CRO) based in the Netherlands. The focus and expertise of the company are in medicinal plants, such as cannabis and molecular farming in general. Innexo BV is part of the Botany Group of companies. To learn more about Innexo BV, visit www.innexo.nl.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201728532/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye